Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADAMTS1
REST API REST API
Homo sapiens
ADAMTS1 is differentially expressed in 255 experiments: 137 organism parts: bone marrow, liver, ... (135 more);, 217 disease states: normal, glioblastoma, ... (215 more);, 95 cell types 482 cell lines 28 compound treatments and 61 other conditions.
Synonyms METH1, KIAA1346, C3-C5
Orthologs ADAMTS1 (Gallus gallus)   Adamts1 (Mus musculus)   adamts1 (Danio rerio)   A7MB07_BOVIN (Bos taurus)   Adamts1 (Rattus norvegicus)   adamts1 (Xenopus laevis)   ADAMTS1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, metalloendopeptidase activity, negative regulation of cell proliferation, metallopeptidase activity, heparin binding, peptidase activity, metal ion binding, extracellular region, basement membrane, integrin-mediated signaling pathway, cytoplasmic vesicle, proteolysis, extracellular matrix, zinc ion binding, kidney development, ovulation from ovarian follicle, heart trabecula formation
InterPro Term Peptidase_M12B_ADAM-TS, Peptidase_M12B_N, ADAM_Cys-rich, ADAM_spacer1, Thrombospondin_1_rpt, Peptidase_M12B, Pept_M12B_ADAM-TS1
UniProt Accession Q6ZP79, Q9UHI8, E5RJR7, E5RI60
Search EB-eye ENSG00000154734
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-17189, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-4717, ... (39 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
MDA468
2
E-MTAB-62, E-MEXP-440
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
T84
2
E-MTAB-37, E-GEOD-1474
U87
2
E-GEOD-20089, E-MEXP-903
476 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (47 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD4+ T cell
1
2
E-GEOD-16190, E-MTAB-24, E-MTAB-25
CD34+ cell
1
E-MEXP-583
fibroblast
1
E-GEOD-3920
primary fibroblast
1
E-MEXP-66
CD19+ B cells (neg. sel.)
1
E-AFMX-5
89 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-TABM-15, E-GEOD-16363, ... (57 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-6014, E-MTAB-37, E-GEOD-4412, E-MTAB-62
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
chronic myelogenous leukemia
2
E-MTAB-62, E-MTAB-37
211 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-GEOD-3356, E-TABM-782, E-GEOD-5824, ... (18 experiments)

Factor Value U/D Experiments
ultrafine particles
1
E-GEOD-4567
5-aza-2'-deoxycytidine
3
1
E-GEOD-5230
vanadium pentoxide
1
E-GEOD-5339
NaOH
1
1
E-MEXP-2590
unknown
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
22 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-22148, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-36, E-GEOD-17476, E-GEOD-21750, E-TABM-321, E-TABM-868, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1432, E-GEOD-19330, ... (21 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-9723, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-2487 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Processing time: 0.354 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM